Results 91 to 100 of about 4,440,004 (198)

Heterogeneous Single/Dual‐Atom Electrocatalysts in Lithium–Sulfur Batteries

ENERGY &ENVIRONMENTAL MATERIALS, EarlyView.
This review summarizes recent advances in single‐atom and dual‐atom electrocatalysts for high‐performance lithium–sulfur batteries. The text systematically covers the classification of catalysts by active metal centers, key synthesis methods, in situ characterization for mechanistic insights, and electrocatalytic mechanisms.
Wenbin Li, Ying Xin, Zhaoliang Zhang, Jin Wang   +3 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). II. Treatments in more advanced clinical development

Epilepsia, EarlyView.
Abstract This article summarizes data for 13 investigational treatments for which at least preliminary seizure outcome data in patients with epilepsy were reported at the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices held in Madrid, Spain, on May 3–6, 2026.
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

Progress report on new epilepsy treatments: A summary of the Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII). I. Treatments in preclinical and early clinical development

Epilepsia, EarlyView.
Abstract Over the last 34 years, the Eilat Conference on New Antiepileptic Drugs and Devices has provided an interactive forum for stakeholders to discuss investigational and recently licensed treatments for seizures and epilepsy. The Eighteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVIII) took place in Madrid, Spain, on May 3 ...
Meir Bialer, Cecilie Johannessen Landmark, Matthias J. Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H. Steve White, Elaine Wirrell   +7 more
wiley   +1 more source

WONOEP appraisal: Biomarkers and treatment strategies beyond the synapse

Epilepsia, EarlyView.
Abstract Epilepsy is a heterogeneous neurological disorder affecting more than 70 million people worldwide, posing significant challenges for clinicians due to its complex etiology, diverse manifestations, variable treatment responses, and the inability to predict seizures or disease onset reliably.
Mirte Scheper, Zining Liu, Aristea S. Galanopoulou, Gernot Hlauschek, Benjamin Sinclair, Wai Lam Leung, Stefanie Dedeurwaerdere, Elisabeth Doran, Solomon L. Moshé, David C. Henshall, Ozlem Akman, Pablo M. Casillas‐Espinosa   +11 more
wiley   +1 more source

The gut microbiome and drug‐resistant epilepsy: Microbiome–antiseizure medication interactions and implications for pharmacoresistance

Epilepsia Open, EarlyView.
Abstract Drug‐resistant epilepsy (DRE) affects approximately one‐third of patients with epilepsy and represents a major unmet clinical need. While traditional hypotheses of pharmacoresistance have focused on alterations in drug targets, efflux transporter overexpression, and intrinsic disease severity, the gut microbiome has recently emerged as a ...
Khaled Zammar, Majd A. AbuAlrob, Musab Ali, Simona Lattanzi, Boulenouar Mesraoua   +4 more
wiley   +1 more source

DECREASE study: A European pool‐analysis of patients with significant reductions in concomitant antiseizure medications in cenobamate Early Access Programs

Epilepsia Open, EarlyView.
Abstract Objective To evaluate the effectiveness and tolerability of cenobamate in patients with a significant reduction in concomitant antiseizure medication (ASM) in European cenobamate Early Access Programs (EAPs). Method Anonymized patient data from real‐world studies/registries associated with European cenobamate EAPs were pooled.
Vicente Villanueva, Simona Lattanzi, Javier Peña‐Ceballos, Rhys H. Thomas, Juan Rodríguez‐Uranga, Zsófia Jordán, Bernhard J. Steinhoff, Randi von Wrede, Norman Delanty, Patrick B. Moloney, Roberta Roberti, Giovanni Boero, Laura Canafoglia, Nicola Specchio, Antonio Gambardella, Edoardo Ferlazzo, Francesca Felicia Operto, Elena Tartara, Hester Garratt, Dániel Fabó, Asier Gómez‐Ibáñez, Gustavo Torres‐Gaona, Yulia Novitskaya, Rainer Surges, Kevin Hampel, Andreas Schulze‐Bonhage   +25 more
wiley   +1 more source

Flexible wearable electronics for cardiovascular monitoring from surface signals to deep physiological insights

FlexMat, EarlyView.
This review organizes flexible wearable electronics for cardiovascular monitoring into four interconnected information layers: surface electrophysiology, hemodynamic sensing, vascular imaging, and biofluid biomarker analysis. This framework clarifies how electrical rhythm, vascular loading, structural and flow‐related features, and biochemical states ...
Qiao Chen, Hongwen Chen, Yuanyuan Li, Pingan Yang, Rui Li, Zhihao Zhou   +5 more
wiley   +1 more source

Engineered molecular diagnostic strategies for hepatocellular carcinoma: Integrating flexible photonic barcodes, liquid biopsies, and AI‐enhanced sensing platforms

FlexMat, EarlyView.
Abstract Early diagnosis of hepatocellular carcinoma (HCC) remains challenging because conventional serum biomarkers, especially alpha‐fetoprotein (AFP), show limited sensitivity for early‐stage disease. Recent progress in engineered molecular diagnostics provides new opportunities to improve HCC detection through integrated material, molecular, and ...
Jingzhi Xue, Wanqi Yang, Xiaoyu Liu, Xuehui Chu, Wei Li, Jinglin Wang   +5 more
wiley   +1 more source

Aumolertinib Versus Osimertinib as First‐Line Treatment for EGFR‐Mutant Non‐Small Cell Lung Cancer: A Retrospective Real‐World Multicenter Study

International Journal of Cancer, EarlyView.
As third‐generation EGFR‐tyrosine kinase inhibitors, both aumolertinib and osimertinib demonstrate clinical efficacy for non‐small cell lung adenocarcinoma, especially in patients with brain metastases. Currently, head‐to‐head studies comparing these two agents in real‐world settings are scarce.
Jinxia Wang, Ping Qi, Jinhua Li, Na Wang, Caihong Fu, Lixin Liu, Shuping Li, Xiao Li, Xiaoming Hou, Hui Qiao   +9 more
wiley   +1 more source

Global Real‐World Outcomes of Olaparib in Metastatic Castration‐Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations

International Journal of Cancer, EarlyView.
ABSTRACT Evidence to guide the treatment for patients with metastatic castration‐resistant prostate cancer (mCRPC) and Homologous Recombination Repair (HRR) gene alterations outside of clinical trials remains limited. This was an observational, cohort study, including mCRPC patients with tumor harboring HRR alterations, progressed on a prior androgen ...
Lorena Incorvaia, Daniele Santini, Marc R. Matrana, Marco Maruzzo, Ray Manneh Kopp, Lorenzo Antonuzzo, Sergio Bracarda, Deniz Tural, Giuseppe Procopio, Maria T. Bourlon, Orazio Caffo, Martin Ignacio Zapata Laguado, Massimo Di Maio, Brigida Anna Maiorano, Vincenza Conteduca, Sabrina Rossetti, Helga Lipari, Thomas Büttner, Mimma Rizzo, Yüksel Ürün, Carlo Messina, Fernando Sabino Marques Monteiro, Andrey Soares, Mattia Puglisi, Alice Principi, Eleonora Lai, Giulia Mammone, Marco Stellato, Ilaria Depetris, Tancredi Didier Bazan Russo, Isadora Yasbick Spricido, Camila Bobato Lara Gismondi, Francesco Massari, Nicola Pavan, Matteo Santoni, Tarek Taha   +35 more
wiley   +1 more source